Sort   by:  
 Page size 
GenomicsZFP91 and IKZF1 Cooperatively Promote IMiD Resistance in T-Cell Lymphomas
ZFP91 and IKZF1 Cooperatively Promote IMiD Resistance in T-Cell Lymphomas
PRJNA723579 | ENA
GenomicsETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [RNA-seq]
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [RNA-seq]
PRJNA1032930 | ENA
GenomicsETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [ChIP-seq]
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [ChIP-seq]
PRJNA1032924 | ENA
GenomicsETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [ATAC-seq]
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [ATAC-seq]
PRJNA1032919 | ENA
TranscriptomicsETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [RNA-seq]
Immunomodulatory Drugs (IMiDs) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance and the mechanism(s) are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers...
ORGANISM(S): Homo sapiens 
2023-10-30 | GSE246435 | GEO
GenomicsETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [ChIP-seq]
Immunomodulatory Drugs (IMiDs) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance and the mechanism(s) are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers...
ORGANISM(S): Homo sapiens 
2023-10-30 | GSE246429 | GEO
GenomicsETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma [ATAC-seq]
Immunomodulatory Drugs (IMiDs) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance and the mechanism(s) are not fully defined. Here, we show that IMiD responses are directed by IMiD-dependent degradation of IKZF1 and IKZF3 that bind to enhancers...
ORGANISM(S): Homo sapiens 
2023-10-30 | GSE246426 | GEO
GenomicsIMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
PRJNA1527400 | ENA
GenomicsIMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
PRJEB125028 | ENA
TranscriptomicsZFP91 and IKZF1 Cooperatively Promote IMiD Resistance in T-Cell Lymphomas
The immunomodulatory (IMiD) agents, such as lenalidomide, are highly effective treatment for several B cell lymphomas but have poor efficacy in T cell lymphomas (TCLs). Here, we show that IKZF1 is a key drug target and vulnerability in lenalidomide sensitive TCL cells. However, TCLs are largely resi...
ORGANISM(S): Homo sapiens 
2022-04-21 | GSE172505 | GEO
Sort   by:  
 Page size